Insider buying last 90 days
No open-market insider purchases were filed for TGTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
TG Therapeutics reported third-quarter 2026 results, with diluted earnings per share of $0.35 against a consensus estimate of $0.26, and revenue of $259.9 million versus an anticipated $245.4 million or $247.2 million depending on source. Net income came in at $55.5 million. U.S. Briumvi net revenue reached $233 million, up 52%, and the company raised its full-year global revenue guidance to $1 billion while pointing to a stronger fourth quarter ahead.
The stock closed at $63.38, up 5.9% on the day, sitting above both its 50-day average of $55.99 and 200-day average of $44.69, with the shorter average above the longer one. It trades near its 52-week high of $63.60. The GekkoIndex reads 45, placing TGTX in the Neutral zone, while the price sits 3.3% above Gekko Fair Value of $61.36.
No confirmed date is on the calendar for the next earnings report. Smart money and unusual options activity show no recorded signals in their respective windows. Seasonality from this point in the calendar has averaged a 13.9% gain over the next 20 trading days across 5 years, rising in 3 of them. Analyst coverage from 3 firms is entirely rated buy, with a consensus target of $69.71, implying 10% upside from current levels. The gap to Gekko Fair Value bears watching given the recent move.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
TG Therapeutics scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
Above 50 and 200-day
Close $64.51 is above the 50-day ($56.70) and 200-day ($45.38) averages, and the 50-day is above the 200-day.
See the chart47, Neutral
Reading 47 is in the Neutral zone.
See the GekkoIndex0.8% below
Price is within 5% of Gekko Fair Value (0.8% below).
See fair valueLeans bearish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earnings+0.7% on average
From this point in the calendar, the next 20 trading days averaged +0.7% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
TG Therapeutics closed at $64.51 on Nov 13, 2026, +108.0% over the past year, inside a 52-week range of $26.76 to $68.03.
Use the left and right arrow keys to read daily values.
Put TGTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
TG Therapeutics is a biopharmaceutical company that has reached the commercial stage, working to acquire, develop and bring to market treatments for B-cell related cancers and autoimmune conditions. It is known for its work on Ublituximab, a glycoengineered monoclonal antibody studied for B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia and relapsing forms of multiple sclerosis, alongside other pipeline candidates aimed at similar patient populations.
Its broader portfolio includes Umbralisib, an oral compound targeting PI3K-delta and CK1-epsilon for use in CLL and lymphoma, Cosibelimab, an antibody aimed at PD-L1, TG-1701, an oral BTK inhibitor, and TG-1801, a bispecific antibody directed at CD47 and CD19. The company also holds licensed preclinical programs covering BET, IRAK4 and GITR, and it works with outside partners on research and development, including Checkpoint Therapeutics, Jiangsu Hengrui Medicine, Novimmune, Ligand Pharmaceuticals, Jubilant Biosys, LFB Biotechnologies, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical and Rhizen Pharmaceuticals.
TG Therapeutics is based in New York City and was established in 1993. Its shares are listed on the NASDAQ under the ticker TGTX.
TG Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47, in the Neutral zone, down 3.2 points over five sessions.
Down 3.2 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 17 | +1.6% | +11.6% | ||
| Accumulation | 201 | +3.2% | +9.2% | ||
| Neutral (current zone) | 420 | +0.6% | +3.5% | ||
| Distribution | 61 | −0.2% | −1.9% | ||
| Selling | 3 | Too few readings yet | |||
Average TGTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
TG Therapeutics trades 0.8% below Gekko Fair Value of $65.02, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what TG Therapeutics shares are worth, recalculated every trading day.
$65.02
Gekko Fair Value, Nov 14, 2026
0.8% below fair value · About fair value
At the end of Aug 2026 the price was 15.2% below the estimate.
No open-market insider purchases were filed for TG Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for TGTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in TGTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
TG Therapeutics has been buying back its own shares.
From company filings.
1signal, 0% of the flagged premium in calls.
Latest: Bearish flow on Nov 11, $284K in unusual premium.
1of the funds Gekko tracks holds TGTX.
TG Therapeutics reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 2 of its last 8 reports.
Feb 25, 2027
Expected before the open, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | $0.05 est $0.41 | $240.3M est $229.8M | −6.3% |
| May 6, 2026 | $0.18 est $0.28 | $204.9M est $200.3M | +19.2% |
| Feb 26, 2026 | $0.14 est $0.33 | $192.6M est $191.8M | +1.4% |
| Nov 3, 2025 | $2.43 est $0.24 | $161.7M est $193.8M | −2.8% |
| Aug 4, 2025 | $0.17 est $0.29 | $141.1M est $146.3M | −18.9% |
| May 5, 2025 | $0.03 est $0.17 | $120.9M est $134.2M | −19.8% |
| Mar 3, 2025 | $0.15 est $0.09 | $108.2M est $108.8M | +18.4% |
| Nov 4, 2024 | $0.02 est $0.03 | $83.88M est $98.79M | −3.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for TG Therapeutics is $77.50, +20.1% from the last close, from 6 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 6 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Bank of America Securities | — | — |
| Nov 10 | Evercore ISI | $71 | +10.1% |
| Nov 9 | TD Cowen | $75 | +16.3% |
| Nov 9 | J.P. Morgan | $72 | +11.6% |
| Sep 21 | H.C. Wainwright | $78 | +20.9% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, TG Therapeutics averaged +0.7% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.4% | 2 of 5 |
| Next 10 trading days | −6.8% | 3 of 5 |
| Next 15 trading days | +1.4% | 1 of 5 |
| Next 20 trading days | +0.7% | 3 of 5 |
| Next 30 trading days | +3.7% | 1 of 5 |
For scale, TGTX’s typical 20-trading-day move in either direction is about 13.5%.
TG Therapeutics’s market cap is $9.75B, with a P/E ratio of 96.4 and revenue of $897.8M over the last twelve months.
Coverage of TG Therapeutics this week reads positive: 8 positive, 2 neutral and 1 negative headlines.
TG Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
TG Therapeutics’s market cap is $9.75B at the Nov 13, 2026 close of $64.51, with 151.1M shares outstanding. The shares trade on a P/E ratio of 96.4.
The consensus analyst 12-month price target for TG Therapeutics is $77.50, +20.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate TG Therapeutics is about fair value: the Nov 13, 2026 close of $64.51 is 0.8% below Gekko Fair Value of $65.02. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
TG Therapeutics is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of $0.56 per share on revenue of $290.2M. TG Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 11.3% on average across the report.
TG Therapeutics’s 52-week high is $68.03 and its 52-week low is $26.76; it closed at $64.51 on Nov 13, 2026, +108.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in TG Therapeutics over the last 30 days, with $0 of flagged premium in calls and $284K in puts. The latest, bearish flow, was on Nov 11, 2026 with $284K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.